Seelos Plans to Study SLS-002 Initially in Suicidality in Major Depressive DisorderNEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today announced an amendment of the agreement with Vyera Pharmaceuticals for the development of SLS-002. This amendment now removes the requirement to conduct a Phase III trial and converts the one-time cash payment obligation otherwise owed to Vyera for commencement of the Phase III trial to a series a cash and stock payments over the next 9 months.
Bay Street News